deltatrials
Completed PHASE1 INTERVENTIONAL 3-arm NCT03392896

Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria

A Placebo-Controlled, Single-Blind, Single-Center Phase 1 Study in Normal Healthy Volunteers and Open-Label Multi-Center Study in Patients With Primary Hyperoxaluria to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of DCR-PHXC Solution for Injection (Subcutaneous Use)

Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Conditions Primary Hyperoxaluria
Interventions DCR-PHXC Placebo
Updated 13 times since 2018 Last updated: Sep 11, 2024 Started: Dec 6, 2017 Primary completion: Nov 19, 2019 Completion: Nov 19, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Primary Hyperoxaluria, this trial is completed. The trial is conducted by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company and has accumulated 13 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Mar 2019 · 4 months · monthly snapshot~Mar 2019 – ~Aug 2019 · 5 months · monthly snapshot~Aug 2019 – ~Feb 2020 · 6 months · monthly snapshot~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshot~Jan 2021 – ~May 2023 · 28 months · monthly snapshot~May 2023 – ~Jul 2024 · 14 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – present · 21 months · monthly snapshot

Change History

13 versions recorded

  1. Oct 2024 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Oct 2024 [monthly]

    Completed PHASE1

  3. Aug 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Jul 2024 — Aug 2024 [monthly]

    Completed PHASE1

  5. May 2023 — Jul 2024 [monthly]

    Completed PHASE1

▶ Show 8 earlier versions

  1. Jan 2021 — May 2023 [monthly]

    Completed PHASE1

  2. Feb 2020 — Jan 2021 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  3. Aug 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE1

  4. Mar 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  5. Nov 2018 — Mar 2019 [monthly]

    Recruiting PHASE1

  6. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE1

  7. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE1

  8. Jan 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

    First recorded

Dec 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations